{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T08:31:53Z","timestamp":1779179513129,"version":"3.51.4"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005202","name":"Muscular Dystrophy Association","doi-asserted-by":"publisher","award":["MDA417129"],"award-info":[{"award-number":["MDA417129"]}],"id":[{"id":"10.13039\/100005202","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1062607"],"award-info":[{"award-number":["APP1062607"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1060482"],"award-info":[{"award-number":["APP1060482"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1159596"],"award-info":[{"award-number":["APP1159596"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1083057"],"award-info":[{"award-number":["APP1083057"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001171","name":"Cancer Institute NSW","doi-asserted-by":"publisher","award":["2019\/CDF008"],"award-info":[{"award-number":["2019\/CDF008"]}],"id":[{"id":"10.13039\/501100001171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.phrs.2020.104680","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T01:55:38Z","timestamp":1581040538000},"page":"104680","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["The potential of the novel NAD+ supplementing agent, SNH6, as a therapeutic strategy for the treatment of Friedreich\u2019s ataxia"],"prefix":"10.1016","volume":"155","author":[{"given":"Shannon","family":"Chiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danuta S.","family":"Kalinowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahendiran","family":"Dharmasivam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nady","family":"Braidy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Des R.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael L.H.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2020.104680_bib0005","doi-asserted-by":"crossref","first-page":"10775","DOI":"10.1073\/pnas.0912925107","article-title":"Mitochondrial iron trafficking and the integration of iron metabolism between the mitochondrion and cytosol","volume":"107","author":"Richardson","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2020.104680_bib0010","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1517\/13543784.12.2.235","article-title":"Friedreich\u2019s ataxia: iron chelators that target the mitochondrion as a therapeutic strategy?","volume":"12","author":"Richardson","year":"2003","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.phrs.2020.104680_bib0015","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1586\/14737175.2014.939173","article-title":"Therapeutic approaches for the treatment of Friedreich\u2019s ataxia","volume":"14","author":"Strawser","year":"2014","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.phrs.2020.104680_bib0020","doi-asserted-by":"crossref","first-page":"16381","DOI":"10.1073\/pnas.0906784106","article-title":"Elucidation of the mechanism of mitochondrial iron loading in Friedreich\u2019s ataxia by analysis of a mouse mutant","volume":"106","author":"Huang","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2020.104680_bib0025","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00109-009-0565-x","article-title":"The ins and outs of mitochondrial iron-loading: the metabolic defect in Friedreich\u2019s ataxia","volume":"88","author":"Richardson","year":"2010","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.phrs.2020.104680_bib0030","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1111\/bph.12470","article-title":"Fixing frataxin:\u2019 ironing out\u2019 the metabolic defect in Friedreich\u2019s ataxia","volume":"171","author":"Anzovino","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2020.104680_bib0035","doi-asserted-by":"crossref","first-page":"20590","DOI":"10.1073\/pnas.1215349109","article-title":"Identification of nonferritin mitochondrial iron deposits in a mouse model of Friedreich ataxia","volume":"109","author":"Whitnall","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2020.104680_bib0040","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/84818","article-title":"Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits","volume":"27","author":"Puccio","year":"2001","journal-title":"Nat. Genet."},{"key":"10.1016\/j.phrs.2020.104680_bib0045","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1016\/j.ajpath.2017.08.021","article-title":"Molecular alterations in a mouse cardiac model of Friedreich Ataxia: an impaired Nrf2 response mediated via upregulation of Keap1 and activation of the Gsk3beta axis","volume":"187","author":"Anzovino","year":"2017","journal-title":"Am. J. Pathol."},{"issue":"Suppl 1","key":"10.1016\/j.phrs.2020.104680_bib0050","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/jnc.12303","article-title":"Mitochondrial pathophysiology in Friedreich\u2019s ataxia","volume":"126","author":"Gonzalez-Cabo","year":"2013","journal-title":"J. Neurochem."},{"key":"10.1016\/j.phrs.2020.104680_bib0055","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1017\/S0317167100006260","article-title":"Complex I and ATP content deficiency in lymphocytes from Friedreich\u2019s Ataxia","volume":"36","author":"Heidari","year":"2009","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.phrs.2020.104680_bib0060","doi-asserted-by":"crossref","first-page":"11492","DOI":"10.1073\/pnas.96.20.11492","article-title":"Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia","volume":"96","author":"Lodi","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2020.104680_bib0065","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.cell.2012.02.035","article-title":"Mitochondria: in sickness and in health","volume":"148","author":"Nunnari","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2020.104680_bib0070","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nm.3510","article-title":"Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich\u2019s ataxia","volume":"20","author":"Perdomini","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2020.104680_bib0075","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neuint.2017.08.002","article-title":"Mitochondrial dysfunction in the neuro-degenerative and cardio-degenerative disease, Friedreich\u2019s ataxia","volume":"117","author":"Chiang","year":"2017","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.phrs.2020.104680_bib0080","doi-asserted-by":"crossref","first-page":"e2237","DOI":"10.1038\/cddis.2016.111","article-title":"\u2019MItochondrial energy imbalance and lipid peroxidation cause cell death in Friedreich\u2019s ataxia\u2019","volume":"7","author":"Abeti","year":"2016","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.phrs.2020.104680_bib0085","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40169-016-0104-7","article-title":"Emerging therapeutic roles for NAD(+) metabolism in mitochondrial and age-related disorders","volume":"5","author":"Srivastava","year":"2016","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.phrs.2020.104680_bib0090","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1212\/WNL.55.11.1719","article-title":"Oxidative stress in patients with Friedreich ataxia","volume":"55","author":"Schulz","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.phrs.2020.104680_bib0095","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1093\/hmg\/dds095","article-title":"Friedreich\u2019s ataxia reveals a mechanism for coordinate regulation of oxidative metabolism via feedback inhibition of the SIRT3 deacetylase","volume":"21","author":"Wagner","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.phrs.2020.104680_bib0100","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0008-6363(01)00357-1","article-title":"Cardiac energetics are abnormal in Friedreich ataxia patients in the absence of cardiac dysfunction and hypertrophy: an in vivo 31P magnetic resonance spectroscopy study","volume":"52","author":"Lodi","year":"2001","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.phrs.2020.104680_bib0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178354","article-title":"Progressive mitochondrial protein lysine acetylation and heart failure in a model of Friedreich\u2019s ataxia cardiomyopathy","volume":"12","author":"Stram","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2020.104680_bib0110","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s12011-018-1366-2","article-title":"Moringa oleifera leaves extract protects titanium dioxide nanoparticles-induced nephrotoxicity via Nrf2\/HO-1 signaling and amelioration of oxidative stress","volume":"187","author":"Abdou","year":"2019","journal-title":"Biol. Trace Elem. Res."},{"key":"10.1016\/j.phrs.2020.104680_bib0115","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.cmet.2012.04.022","article-title":"The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity","volume":"15","author":"Canto","year":"2012","journal-title":"Cell Metab."},{"key":"10.1016\/j.phrs.2020.104680_bib0120","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12883-015-0272-x","article-title":"Effect of nicotinamide mononucleotide on brain mitochondrial respiratory deficits in an Alzheimer\u2019s disease-relevant murine model","volume":"15","author":"Long","year":"2015","journal-title":"BMC Neurol."},{"key":"10.1016\/j.phrs.2020.104680_bib0125","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.tem.2012.06.005","article-title":"The dynamic regulation of NAD metabolism in mitochondria","volume":"23","author":"Stein","year":"2012","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2020.104680_bib0130","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.tibs.2006.11.006","article-title":"NAD+ metabolism in health and disease","volume":"32","author":"Belenky","year":"2007","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.phrs.2020.104680_bib0135","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/283593a0","article-title":"(ADP-ribose)n participates in DNA excision repair","volume":"283","author":"Durkacz","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2020.104680_bib0140","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.cmet.2014.04.001","article-title":"NAD+-Dependent activation of Sirt1 corrects the phenotype in a mouse model of mitochondrial disease","volume":"19","author":"Cerutti","year":"2014","journal-title":"Cell Metab."},{"key":"10.1016\/j.phrs.2020.104680_bib0145","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1002\/jnr.21498","article-title":"Mechanisms of impaired mitochondrial energy metabolism in acute and chronic neurodegenerative disorders","volume":"85","author":"Soane","year":"2007","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.phrs.2020.104680_bib0150","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.mad.2015.04.001","article-title":"PARP-1 involvement in neurodegeneration: a focus on Alzheimer\u2019s and Parkinson\u2019s diseases","volume":"146\u2013148","author":"Martire","year":"2015","journal-title":"Mech. Ageing Dev."},{"key":"10.1016\/j.phrs.2020.104680_bib0155","doi-asserted-by":"crossref","first-page":"543","DOI":"10.18632\/aging.100326","article-title":"Interference between PARPs and SIRT1: a novel approach to healthy ageing?","volume":"3","author":"Canto","year":"2011","journal-title":"Aging"},{"key":"10.1016\/j.phrs.2020.104680_bib0160","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.cmet.2011.08.014","article-title":"Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice","volume":"14","author":"Yoshino","year":"2011","journal-title":"Cell Metab."},{"key":"10.1016\/j.phrs.2020.104680_bib0165","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/hep.1840150323","article-title":"Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture","volume":"15","author":"Baker","year":"1992","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2020.104680_bib0170","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S0022-2143(98)90180-9","article-title":"Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease","volume":"131","author":"Richardson","year":"1998","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.phrs.2020.104680_bib0175","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1124\/pr.57.4.2","article-title":"The evolution of iron chelators for the treatment of iron overload disease and cancer","volume":"57","author":"Kalinowski","year":"2005","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.phrs.2020.104680_bib0180","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0925-4439(01)00041-2","article-title":"Development of potential iron chelators for the treatment of Friedreich\u2019s ataxia: ligands that mobilize mitochondrial iron","volume":"1536","author":"Richardson","year":"2001","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.phrs.2020.104680_bib0185","doi-asserted-by":"crossref","first-page":"9757","DOI":"10.1073\/pnas.0804261105","article-title":"The MCK mouse heart model of Friedreich\u2019s ataxia: alterations in iron-regulated proteins and cardiac hypertrophy are limited by iron chelation","volume":"105","author":"Whitnall","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2020.104680_bib0190","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1124\/mol.113.090357","article-title":"Potent antimycobacterial activity of the pyridoxal isonicotinoyl hydrazone analog 2-pyridylcarboxaldehyde isonicotinoyl hydrazone: a lipophilic transport vehicle for isonicotinic acid hydrazide","volume":"85","author":"Ellis","year":"2014","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.phrs.2020.104680_bib0195","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s10953-016-0504-8","article-title":"Acid-base properties and kinetics of hydrolysis of aroylhydrazones derived from nicotinic acid hydrazide","volume":"45","author":"Benkovic","year":"2016","journal-title":"J. Solution Chem."},{"key":"10.1016\/j.phrs.2020.104680_bib0200","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0304-4165(02)00478-6","article-title":"Hydrolysis of pyridoxal isonicotinoyl hydrazone and its analogs","volume":"1619","author":"Buss","year":"2003","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.phrs.2020.104680_bib0205","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1021\/jm7012562","article-title":"Structure-activity relationships of novel iron chelators for the treatment of iron overload disease: the methyl pyrazinylketone isonicotinoyl hydrazone series","volume":"51","author":"Kalinowski","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2020.104680_bib0210","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bbadis.2004.09.001","article-title":"PCTH: a novel orally active chelator of the aroylhydrazone class that induces iron excretion from mice","volume":"1739","author":"Wong","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.phrs.2020.104680_bib0215","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.ajpath.2013.05.032","article-title":"Molecular and functional alterations in a mouse cardiac model of Friedreich ataxia: activation of the integrated stress response, eIF2alpha phosphorylation, and the induction of downstream targets","volume":"183","author":"Huang","year":"2013","journal-title":"Amr. J. Pathol."},{"key":"10.1016\/j.phrs.2020.104680_bib0220","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s12640-017-9795-9","article-title":"Targeting sentinel proteins and extrasynaptic glutamate receptors: a therapeutic strategy for preventing the effects elicited by perinatal asphyxia?","volume":"33","author":"Herrera-Marschitz","year":"2018","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.phrs.2020.104680_bib0225","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11306-017-1310-z","article-title":"Quantifying the cellular NAD+ metabolome using a tandem liquid chromatography mass spectrometry approach","volume":"14","author":"Bustamante","year":"2017","journal-title":"Metabolomics"},{"key":"10.1016\/j.phrs.2020.104680_bib0230","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10522-013-9489-5","article-title":"Mapping NAD(+) metabolism in the brain of ageing Wistar rats: potential targets for influencing brain senescence","volume":"15","author":"Braidy","year":"2014","journal-title":"Biogerontology"},{"key":"10.1016\/j.phrs.2020.104680_bib0235","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/cbic.200400330","article-title":"Direct quantitation of poly(ADP-ribose) polymerase (PARP) activity as a means to distinguish necrotic and apoptotic death in cell and tissue samples","volume":"6","author":"Putt","year":"2005","journal-title":"ChemBioChem"},{"key":"10.1016\/j.phrs.2020.104680_bib0240","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.phrs.2020.104680_bib0245","first-page":"E197","article-title":"Age-related increase in mitochondrial proton leak and decrease in ATP turnover reactions in mouse hepatocytes","volume":"275","author":"Harper","year":"1998","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.phrs.2020.104680_bib0250","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1182\/blood.V86.11.4295.bloodjournal86114295","article-title":"The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents","volume":"86","author":"Richardson","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2020.104680_bib0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0167-4889(90)90018-9","article-title":"The uptake of iron and transferrin by the human malignant melanoma cell","volume":"1053","author":"Richardson","year":"1990","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.phrs.2020.104680_bib0260","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1182\/blood-2004-03-0868","article-title":"Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment","volume":"104","author":"Yuan","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2020.104680_bib0265","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat. Meth."},{"key":"10.1016\/j.phrs.2020.104680_bib0270","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1089\/ars.2011.3921","article-title":"Mitochondrial mayhem: the mitochondrion as a modulator of iron metabolism and its role in disease","volume":"15","author":"Huang","year":"2011","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.phrs.2020.104680_bib0275","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.celrep.2015.09.023","article-title":"Lethal cardiomyopathy in mice lacking transferrin receptor in the heart","volume":"13","author":"Xu","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.phrs.2020.104680_bib0280","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1089\/ars.2017.7415","article-title":"Mitochondrial NAD(+)\/NADH redox state and diabetic cardiomyopathy","volume":"30","author":"Berthiaume","year":"2019","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.phrs.2020.104680_bib0285","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.acvd.2015.10.004","article-title":"Nicotinamide adenine dinucleotide homeostasis and signalling in heart disease: pathophysiological implications and therapeutic potential","volume":"109","author":"Mericskay","year":"2016","journal-title":"Arch. Cardiovasc. Dis."},{"key":"10.1016\/j.phrs.2020.104680_bib0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cld.2016.08.001","article-title":"Drug metabolism in the liver","volume":"21","author":"Almazroo","year":"2017","journal-title":"Clin. Liver Dis. (Hoboken)"},{"key":"10.1016\/j.phrs.2020.104680_bib0295","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1042\/BJ20130079","article-title":"Biochemistry of cardiomyopathy in the mitochondrial disease Friedreich\u2019s ataxia","volume":"453","author":"Lane","year":"2013","journal-title":"Biochem. J."},{"key":"10.1016\/j.phrs.2020.104680_bib0300","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s12012-018-9462-2","article-title":"Poly(ADP-ribose) polymerase (PARP) and PARP inhibitors: mechanisms of action and role in cardiovascular disorders","volume":"18","author":"Henning","year":"2018","journal-title":"Cardiovasc. Toxicol."},{"key":"10.1016\/j.phrs.2020.104680_bib0305","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.tcb.2014.04.002","article-title":"NAD+ and sirtuins in aging and disease","volume":"24","author":"Imai","year":"2014","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.phrs.2020.104680_bib0310","article-title":"Frataxin deficiency promotes excess microglial DNA damage and inflammation that is rescued by PJ34","volume":"11","author":"Shen","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2020.104680_bib0315","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1042\/BJ20101116","article-title":"The Friedreich\u2019s ataxia protein frataxin modulates DNA base excision repair in prokaryotes and mammals","volume":"432","author":"Thierbach","year":"2010","journal-title":"Biochem. J."},{"key":"10.1016\/j.phrs.2020.104680_bib0320","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000812","article-title":"Altered gene expression and DNA damage in peripheral blood cells from Friedreich\u2019s ataxia patients: cellular model of pathology","volume":"6","author":"Haugen","year":"2010","journal-title":"PLoS Genet."},{"key":"10.1016\/j.phrs.2020.104680_bib0325","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.expneurol.2009.03.020","article-title":"Poly(ADP-ribose) signals to mitochondrial AIF: a key event in parthanatos","volume":"218","author":"Wang","year":"2009","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.phrs.2020.104680_bib0330","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1046\/j.1471-4159.2003.01684.x","article-title":"Poly(ADP-ribose) polymerase-1 activity promotes NF-kappaB-driven transcription and microglial activation: implication for neurodegenerative disorders","volume":"85","author":"Chiarugi","year":"2003","journal-title":"J. Neurochem."},{"key":"10.1016\/j.phrs.2020.104680_bib0335","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1006\/bbrc.2001.5115","article-title":"Poly(ADP-ribosyl)ation of transcription factor Yin Yang 1 under conditions of DNA damage","volume":"285","author":"Oei","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2020.104680_bib0340","doi-asserted-by":"crossref","first-page":"884S","DOI":"10.3945\/ajcn.110.001917","article-title":"Regulation of PGC-1\u03b1, a nodal regulator of mitochondrial biogenesis","volume":"93","author":"Fernandez-Marcos","year":"2011","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.phrs.2020.104680_bib0345","first-page":"291","article-title":"NAD+ as a signaling molecule modulating metabolism, Cold Spring Harb","volume":"76","author":"Canto","year":"2011","journal-title":"Int. J. Quantum Chem. Quantum Biol. Symp."},{"key":"10.1016\/j.phrs.2020.104680_bib0350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12311-010-0212-7","article-title":"Combined therapy with idebenone and deferiprone in patients with Friedreich\u2019s ataxia","volume":"10","author":"Velasco-Sanchez","year":"2010","journal-title":"Cerebellum"},{"key":"10.1016\/j.phrs.2020.104680_bib0355","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1148\/radiol.11111329","article-title":"Endothelial cell-derived microparticles loaded with iron oxide nanoparticles: feasibility of MR imaging monitoring in mice","volume":"263","author":"Al Faraj","year":"2012","journal-title":"Radiology"},{"key":"10.1016\/j.phrs.2020.104680_bib0360","doi-asserted-by":"crossref","DOI":"10.1177\/1759091415578713","article-title":"Prostaglandin E2 EP2 receptor deletion attenuates intracerebral hemorrhage-induced brain injury and improves functional recovery","volume":"7","author":"Leclerc","year":"2015","journal-title":"ASN Neuro"},{"key":"10.1016\/j.phrs.2020.104680_bib0365","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019194","article-title":"Age related changes in NAD+ metabolism oxidative stress and Sirt1 activity in wistar rats","volume":"6","author":"Braidy","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2020.104680_bib0370","doi-asserted-by":"crossref","first-page":"20408","DOI":"10.1074\/jbc.M109.016469","article-title":"Enzymes in the NAD+ salvage pathway regulate SIRT1 activity at target gene promoters","volume":"284","author":"Zhang","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2020.104680_bib0375","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cmet.2015.05.023","article-title":"NAD(+) metabolism and the control of energy homeostasis: a balancing act between mtochondria and the nucleus","volume":"22","author":"Canto","year":"2015","journal-title":"Cell Metab."},{"key":"10.1016\/j.phrs.2020.104680_bib0380","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1093\/hmg\/ddy278","article-title":"Rescue of biosynthesis of nicotinamide adenine dinucleotide protects the heart in cardiomyopathy caused by lamin A\/C gene mutation","volume":"27","author":"Vignier","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.phrs.2020.104680_bib0385","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.yexcr.2018.10.003","article-title":"PARP-1 inhibition protects the diabetic heart through activation of SIRT1-PGC-1alpha axis","volume":"373","author":"Waldman","year":"2018","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.phrs.2020.104680_bib0390","first-page":"75","article-title":"Poly(ADP-ribose) polymerases as modulators of mitochondrial activity, Trends Endocrinol","volume":"26","author":"Bai","year":"2015","journal-title":"Metab."},{"key":"10.1016\/j.phrs.2020.104680_bib0395","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.cell.2014.03.026","article-title":"Defective mitophagy in XPA via PARP-1 hyperactivation and NAD(+)\/SIRT1 reduction","volume":"157","author":"Fang","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2020.104680_bib0400","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0165-6147(99)01292-4","article-title":"Poly (ADP-ribose) polymerase, nitric oxide and cell death","volume":"20","author":"Pieper","year":"1999","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.phrs.2020.104680_bib0405","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1089\/ars.2017.7216","article-title":"NAD(H) and NADP(H) redox couples and cellular energy metabolism","volume":"28","author":"Xiao","year":"2018","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.phrs.2020.104680_bib0410","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1002\/pmic.200701049","article-title":"Proteomic analysis of hearts from frataxin knockout mice: marked rearrangement of energy metabolism, a response to cellular stress and altered expression of proteins involved in cell structure, motility and metabolism","volume":"8","author":"Sutak","year":"2008","journal-title":"Proteomics"},{"key":"10.1016\/j.phrs.2020.104680_bib0415","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1101\/gad.183509.111","article-title":"On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1","volume":"26","author":"Luo","year":"2012","journal-title":"Genes Dev."},{"key":"10.1016\/j.phrs.2020.104680_bib0420","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1161\/CIRCRESAHA.118.312498","article-title":"Sirtuins and NAD(+) in the development and treatment of metabolic and cardiovascular diseases","volume":"123","author":"Kane","year":"2018","journal-title":"Circ. Res."},{"key":"10.1016\/j.phrs.2020.104680_bib0425","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1161\/CIRCULATIONAHA.109.917922","article-title":"Thyroid replacement therapy and heart failure","volume":"122","author":"Gerdes","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2020.104680_bib0430","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000469708","article-title":"Cardiac thyroid hormone metabolism and heart failure","volume":"6","author":"Janssen","year":"2017","journal-title":"Eur. Thyroid J."},{"key":"10.1016\/j.phrs.2020.104680_bib0435","doi-asserted-by":"crossref","first-page":"R67","DOI":"10.1530\/JOE-15-0133","article-title":"The molecular basis of the non-thyroidal illness syndrome","volume":"225","author":"de Vries","year":"2015","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.phrs.2020.104680_bib0440","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070097","article-title":"SIRT1 is a direct coactivator of thyroid hormone receptor beta1 with gene-specific actions","volume":"8","author":"Suh","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2020.104680_bib0445","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.tips.2006.10.003","article-title":"Novel modulators of poly(ADP-ribose) polymerase","volume":"27","author":"Szabo","year":"2006","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.phrs.2020.104680_bib0450","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1527-3466.2007.00018.x","article-title":"Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors","volume":"25","author":"Pacher","year":"2007","journal-title":"Cardiovasc. Drug Rev."},{"key":"10.1016\/j.phrs.2020.104680_bib0455","doi-asserted-by":"crossref","first-page":"C948","DOI":"10.1152\/ajpcell.1989.257.5.C948","article-title":"Hyperthyroid adult rat cardiomyocytes. I. Nucleotide content, beta- and alpha-adrenoreceptors, and cAMP production","volume":"257","author":"Hohl","year":"1989","journal-title":"Am. J. Physiol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819329032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819329032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T03:21:25Z","timestamp":1777605685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661819329032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":91,"alternative-id":["S1043661819329032"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2020.104680","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The potential of the novel NAD+ supplementing agent, SNH6, as a therapeutic strategy for the treatment of Friedreich\u2019s ataxia","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2020.104680","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104680"}}